Senti Biosciences to spin off SENTI-202 assets to Celadon-backed NewCo for CVR worth up to $60 million
SNTI•Contingent value right consideration
The consideration is a contingent value right distributed to equity holders, with potential milestone payments of up to $60 million over seven years.
The milestones are:
- $10 million on BLA filing and acceptance
- $20 million on FDA approval
- $30 million when cumulative net sales reach $200 million
Senti to retain Regulator Dial platform
Senti Biosciences Holdings will retain the Regulator Dial platform, pivoting to controllable genetic medicines and seeking additional financing to fund early-stage programs.
Spin-off of Gene-Circuit pipeline assets
Senti Biosciences will spin off its SENTI-202 assets to a Celadon-controlled NewCo. The transaction covers Senti Biosciences Holdings’ Gene-Circuit pipeline assets, including rights to the AML therapy SENTI-202.
